Amendment# 1 to the Second Amended and Restated License Agreement dated May 9, 2016ADC Therapeutics SA • August 14th, 2019 • Pharmaceutical preparations
This Amendment# 1 (“Amendment #1”) dated 19 September 2018 (“Amendment Effective Date”) is made by and between ADC Products (UK) Ltd., with registered address at registered office is at 4th Floor, Reading Bridge House, George Street, Reading, Berkshire RG l 8LS, United Kingdom (“ADCP”), ADC Therapeutics SA, with registered address at Route de la Corniche 3B, 1066 Epalinges, Switzerland (“ADCT”), and Medimmune Ltd., with registered office at Milstein Building, Granta Park, Cambridge CB21 6GH (“Medlmmune”), each hereinafter individually referred to as “Party” and jointly as “Parties”.
Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) would likely cause competitive harm to ADC Therapeutics...License Agreement • August 14th, 2019 • ADC Therapeutics SA • Pharmaceutical preparations
This Second Amended and Restated License Agreement (“Agreement”) is made and entered into as of May 9, 2016 (“Execution Date”), by and among:
